Homologous and Heterologous Vaccine Boost Strategies for Humoral and Cellular Immunologic Coverage of the SARS-CoV-2 Omicron Variant

  1. C. Sabrina Tan
  2. Ai-ris Y. Collier
  3. Jinyan Liu
  4. Jingyou Yu
  5. Abishek Chandrashekar
  6. Katherine McMahan
  7. Huahua Wan
  8. Xuan He
  9. Catherine Jacob-Dolan
  10. Daniel Sellers
  11. John D. Ventura
  12. Yannic Bartsch
  13. Blake M. Hauser
  14. Jennifer E. Munt
  15. Melissa Mattocks
  16. Kathryn E. Stephenson
  17. Samuel J. Vidal
  18. Kate Jaegle
  19. Marjorie Rowe
  20. Rachel Hemond
  21. Lorraine Bermudez Rivera
  22. Tochi Anioke
  23. Julia Barrett
  24. Benjamin Chung
  25. Sarah Gardner
  26. Makda S. Gebre
  27. Nicole Hachmann
  28. Michelle Lifton
  29. Jessica Miller
  30. Felix Nampanya
  31. Olivia Powers
  32. Michaela Sciacca
  33. Mazuba Siamatu
  34. Nehalee Surve
  35. Lisa H. Tostanoski
  36. Haley VanWyk
  37. Cindy Wu
  38. Ralph S. Baric
  39. Aaron G. Schmidt
  40. Galit Alter
  41. Dan H. Barouch
1 evaluations Published on
Read the full article Related papers
This article on Sciety

Abstract

The rapid spread of the highly mutated SARS-CoV-2 Omicron variant has raised substantial concerns about the protective efficacy of currently available vaccines. We assessed Omicron-specific humoral and cellular immune responses in 65 individuals who were vaccinated with two immunizations of BNT162b2 and were boosted after at least 6 months with either Ad26.COV2.S (Johnson & Johnson; N=41) or BNT162b2 (Pfizer; N=24) (Table S1).

Related articles

Related articles are currently not available for this article.